Request Appointment
619 19th St SBirmingham, AL 35249
Fax+1 205-975-7837
Overview of Dr. Vachhani
Dr. Pankit Vachhani is an oncologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including University of Alabama Hospital, USA Health University Hospital, and Russell Medical. He received his medical degree from Weill Cornell Medical College in Qatar and has been in practice 5 years. He is one of 75 doctors at University of Alabama Hospital and one of 36 doctors at USA Health University Hospital who specialize in Oncology. He has more than 60 publications and over 500 citings.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 2018
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2012 - 2015
Weill Cornell Medical College in QatarClass of 2012
Certifications & Licensure
AL State Medical License 2018 - 2025
VA State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- NTX-301 in MDS/AML Start of enrollment: 2021 Jan 06
Publications & Presentations
PubMed
- Quality-Adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:...Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, Pau Montesinos, Pankit Vachhani
Cancer Medicine. 2025-04-01 - BPI25-014: Pacritinib in Patients With Intermediate-1 Risk Myelofibrosis: Outcomes From Post-Hoc Analysis of Two Phase 3 Studies.Pankit Vachhani, Nikolai Podoltsev, Ashwin Kishtagari, Purvi Suthar, Michael Vredenburg
Journal of the National Comprehensive Cancer Network. 2025-03-28 - Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study.Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, Hsin-An Hou, Grzegorz Helbig
Blood Advances. 2025-03-11
Journal Articles
- Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center ExperiencePankit Vachhani, Evelena P Ontiveros, Leukemia Research
- Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center ExperiencePankit Vachhani, Evelena P Ontiveros, Leukemia Research
Abstracts/Posters
- Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant AbstractPankit Vachhani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE¬ (Bispecific T-Cell Engager) in Patients with R...Pankit Vachhani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center ExperienceOctober 2018
Press Mentions
Asymptomatic or Minimally Symptomatic MyelofibrosisNovember 4th, 2024- Systemic Mastocytosis: Information for Patients and CaregiversAugust 26th, 2024
- Risk Stratification in Myelofibrosis: Which Model Should You Use?July 3rd, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
